Fulgent Presents Updated FID-007 Data at ASCO 2026
Fulgent Genetics presented updated Phase 2 data for FID-007 in combination with cetuximab for recurrent or metastatic head and neck squamous cell carcinoma at the ASCO 2026 Annual Meeting. The study showed an objective response rate of 61.9%, median progression-free survival of 6.7 months, and one-year overall survival of 63.4% in patients who progressed after PD-1 therapy.
Key figures
- Drug Name
- FID-007
- Phase Of Trial
- Phase 2
- Orr
- 61.9%
- Median dor
- 7.4 months
- Median pfs
- 6.7 months
- One year os
- 63.4%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.